TLDR
- Tenax Therapeutics stock dropped 84.2% in pre-market trading on August 10, 2026
- The Phase 3 LEVEL trial of TNX-103 failed to meet its primary endpoint in 6-minute walk distance vs placebo
- The trial also missed its key secondary endpoint on patient-reported symptom scores
- Multiple Wall Street analysts had recently initiated or raised price targets, some as high as $50
- Subgroup data showed stronger effects in sicker patients, which may guide Tenax’s next regulatory move
Tenax Therapeutics stock cratered 84.2% in pre-market trading on August 10, 2026, after its Phase 3 LEVEL trial of TNX-103 failed to hit its primary endpoint.
Tenax Therapeutics, Inc., TENX
The trial tested oral levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). It missed the primary endpoint of a statistically meaningful improvement in 6-minute walk distance versus placebo, with a least-squares mean difference of just 3.5 meters and a p-value of 0.63.
That p-value is a long way from statistical significance. For context, a p-value of 0.05 or lower is typically required.
🚨 $TENX (Tenax Therapeutics) Phase 3 LEVEL Trial Update
The main endpoint was missed…
but biomarker signals and subgroup activity keep the TNX-103 story alive 👀
📊 KEY CLINICAL RESULTS (PHASE 3 LEVEL)🔹 Trial: LEVEL Phase 3
🔹 Patient Population: PH-HFpEF
🔹 Patients…— Emmanuel – Big Tech & AI Investor (@EmmanuelInvest) August 10, 2026
The trial also missed its key secondary endpoint, which measured improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score. That double miss hit investor confidence hard.
The pain was made worse by how bullish sentiment had been heading into the readout. Chardan, Guggenheim, Piper Sandler, Canaccord, and Evercore ISI had all recently either started coverage or raised their price targets on TENX. Some targets reached as high as $50.
Tenax had also brought on a Chief Commercial Officer in anticipation of a potential product launch. That hire now looks early.
What the Data Actually Showed
Not everything in the trial was negative. TNX-103 was reported as generally safe and well tolerated across the study population.
Exploratory analysis showed TNX-103 produced a 49% reduction in NT-proBNP, a marker of cardiac wall stress. It also delivered a 3.5 mmHg placebo-controlled reduction in right ventricular systolic pressure.
In a subgroup of patients with a baseline walk distance below the median of 333 meters, TNX-103 improved 6-minute walk distance by 26.3 meters versus placebo. That is the data point Tenax will likely anchor its next regulatory conversation around.
The company said it is preparing for regulatory discussions on revising its strategy, with a potential focus on more severely affected PH-HFpEF patients.
Market Context
The broader market was not a factor in Monday’s drop. S&P 500 futures were pointing modestly higher in pre-market, supported by softer-than-expected July jobs data from the prior Friday. The Nasdaq was up 0.2% and the S&P 500 up 0.03%.
The collapse in TENX was entirely company-specific.
PH-HFpEF remains a condition with no approved therapies, which had been a core part of the bull case for TNX-103.
The most recent analyst rating on TENX is a Buy with a $35.00 price target, though that was set before the trial readout.
As of the trial announcement, Tenax has no revenue and widening losses. Its market cap stood at $503 million before the pre-market drop.
The company’s next steps hinge on whether regulators will consider a narrower path forward targeting the sicker patient subgroup where TNX-103 appeared to show a more meaningful effect.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
